{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T03:57:38Z","timestamp":1781236658119,"version":"3.54.1"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ejpb.2026.115123","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T16:15:27Z","timestamp":1779812127000},"page":"115123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Preclinical evaluation of 89Zr\/177Lu\/161Tb-labeled anti-CD228 monoclonal antibody for theranostics in skin cutaneous melanoma"],"prefix":"10.1016","volume":"225","author":[{"given":"Xiaofei","family":"Hao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binwei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingming","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huayan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Decai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanjie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6348-0636","authenticated-orcid":false,"given":"Xiaobo","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2026.115123_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.envres.2023.115771","article-title":"Therapeutic potential of marine peptides in malignant melanoma","volume":"227","author":"Ahmed","year":"2023","journal-title":"Environ. Res."},{"issue":"1","key":"10.1016\/j.ejpb.2026.115123_b0010","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"10400","key":"10.1016\/j.ejpb.2026.115123_b0015","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0140-6736(23)00821-8","article-title":"Cutaneous melanoma","volume":"402","author":"Long","year":"2023","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ejpb.2026.115123_b0020","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.ejpb.2026.115123_b0025","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1158\/1078-0432.CCR-21-0809","article-title":"5-Year outcomes with cobimetinib plus vemurafenib in BRAFV600 mutation-positive advanced melanoma: extended follow-up of the coBRIM study","volume":"27","author":"Ascierto","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejpb.2026.115123_b0030","article-title":"COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients withBRAFV600-Mutant Melanoma [published correction appears in","author":"Dummer","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejpb.2026.115123_b0035","doi-asserted-by":"crossref","unstructured":"de Almeida Gon\u00e7alves VDM, de Almeida Camargo Filho MF, Zaleski T, Rodrigues Vilas Boas R, Rossi Ribeiro E, Saad Vaz R, et al. Chemotherapy in focus: A meta-analysis confronts immunotherapy in the treatment of advanced melanoma. Crit Rev Oncol Hematol. 2021;161:103304.","DOI":"10.1016\/j.critrevonc.2021.103304"},{"issue":"10","key":"10.1016\/j.ejpb.2026.115123_b0040","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/s41419-020-03124-2","article-title":"The membrane-bound and soluble form of melanotransferrin function independently in the diagnosis and targeted therapy of lung cancer","volume":"11","author":"Lei","year":"2020","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.ejpb.2026.115123_b0045","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/CMR.0000000000000741","article-title":"Melanotransferrin is efficiently sorted on the surface of exosomes secreted by melanoma cells","volume":"31","author":"Bonhoure","year":"2021","journal-title":"Melanoma Res."},{"issue":"4","key":"10.1016\/j.ejpb.2026.115123_b0050","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1158\/1535-7163.MCT-22-0401","article-title":"SGN-CD228A is an Investigational CD228-directed antibody-drug conjugate with potent antitumor activity across a wide spectrum of preclinical solid tumor models","volume":"22","author":"Mazahreh","year":"2023","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.ejpb.2026.115123_b0055","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1073\/pnas.83.5.1261","article-title":"Primary structure of the human melanoma-associated antigen p97 (melanotransferrin) deduced from the mRNA sequence","volume":"83","author":"Rose","year":"1986","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"12","key":"10.1016\/j.ejpb.2026.115123_b0060","first-page":"6551","article-title":"Pattern of melanotransferrin expression in human colorectal tissues: an immunohistochemical study on potential clinical application","volume":"35","author":"Du\u015b-Szachniewicz","year":"2015","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.ejpb.2026.115123_b0065","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0006-8993(96)88505-2","article-title":"Coincident expression and distribution of melanotransferrin and transferrin receptor in human brain capillary endothelium","volume":"712","author":"Rothenberger","year":"1996","journal-title":"Brain Res."},{"issue":"2","key":"10.1016\/j.ejpb.2026.115123_b0070","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.bbagen.2004.12.002","article-title":"Examination of the distribution of the transferrin homologue, melanotransferrin (tumour antigen p97), in mouse and human","volume":"1722","author":"Sekyere","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"issue":"11","key":"10.1016\/j.ejpb.2026.115123_b0075","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1093\/carcin\/bgl045","article-title":"The function of melanotransferrin: a role in melanoma cell proliferation and tumorigenesis","volume":"27","author":"Dunn","year":"2006","journal-title":"Carcinogenesis"},{"issue":"2","key":"10.1016\/j.ejpb.2026.115123_b0080","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.yexcr.2005.05.004","article-title":"Stimulation of cell surface plasminogen activation by membrane-bound melanotransferrin: a key phenomenon for cell invasion","volume":"308","author":"Michaud-Levesque","year":"2005","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.ejpb.2026.115123_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.109890","article-title":"LncRNA MFI2-AS1 promotes HCC progression and metastasis by acting as a competing endogenous RNA of miR-134 to upregulate FOXM1 expression","volume":"125","author":"Wei","year":"2020","journal-title":"Biomed. Pharmacother."},{"issue":"4","key":"10.1016\/j.ejpb.2026.115123_b0090","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12632","article-title":"Non-coding RNA MFI2-AS1 promotes colorectal cancer cell proliferation, migration and invasion through miR-574-5p\/MYCBP axis","volume":"52","author":"Li","year":"2019","journal-title":"Cell Prolif."},{"key":"10.1016\/j.ejpb.2026.115123_b0095","doi-asserted-by":"crossref","unstructured":"Yu T, Tong L, Ao Y, Zhang G, Liu Y, Zhang H. Upregulation of TRIAP1 by the lncRNA MFI2-AS1\/miR-125a-5p Axis Promotes Thyroid Cancer Tumorigenesis. Onco Targets Ther. 2020;13:6967-6974. Published 2020 Jul 17.","DOI":"10.2147\/OTT.S236476"},{"key":"10.1016\/j.ejpb.2026.115123_b0100","unstructured":"[Internet]First in China: Boan Biotech\u2019s Novel Investigational CD228-Directed ADC Approved for Clinical Trials.26 July 2024. https:\/\/www.boan-bio.com\/en\/info.php?id=313."},{"key":"10.1016\/j.ejpb.2026.115123_b0105","article-title":"Good practices for 89Zr radiopharmaceutical production and quality control","volume":"9(1):40","author":"Wuensche","year":"2024","journal-title":"EJNMMI Radiopharm. Chem."},{"issue":"13","key":"10.1016\/j.ejpb.2026.115123_b0110","doi-asserted-by":"crossref","first-page":"6274","DOI":"10.7150\/thno.107209","article-title":"GPA33-pretargeted radioimmunotherapy with mono- and bivalent DOTA-based Lu-177-labeled radiohaptens in a mouse orthotopic liver xenograft model of metastatic human colorectal cancer","volume":"15","author":"Le Roux","year":"2025","journal-title":"Theranostics"},{"issue":"8","key":"10.1016\/j.ejpb.2026.115123_b0115","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.2967\/jnumed.121.262713","article-title":"Prostate-specific membrane antigen radioligand therapy using 177Lu-PSMA I&T and 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: comparison of safety, biodistribution, and dosimetry","volume":"63","author":"Schuchardt","year":"2022","journal-title":"J. Nucl. Med."},{"issue":"12","key":"10.1016\/j.ejpb.2026.115123_b0120","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2026.115123_b0125","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231187202","article-title":"Novel radionuclide therapy combinations in prostate cancer","volume":"15","author":"Inderjeeth","year":"2023","journal-title":"Ther Adv Med Oncol."},{"key":"10.1016\/j.ejpb.2026.115123_b0130","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231179309","article-title":"Determinants of outcome following PSMA-based radioligand therapy and mechanisms of resistance in patients with metastatic castration-resistant prostate cancer","volume":"15","author":"Kostos","year":"2023","journal-title":"Ther Adv Med Oncol."},{"key":"10.1016\/j.ejpb.2026.115123_b0135","article-title":"Theranostic terbium radioisotopes: challenges in production for clinical application","volume":"8","author":"Naskar","year":"2021","journal-title":"Front Med (lausanne)."},{"issue":"1","key":"10.1016\/j.ejpb.2026.115123_b0140","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40658-022-00495-7","article-title":"Active bone marrow S-values for the low-energy electron emitter terbium-161 compared to S-values for lutetium-177 and yttrium-90","volume":"9","author":"Hemmingsson","year":"2022","journal-title":"EJNMMI Phys."},{"key":"10.1016\/j.ejpb.2026.115123_b0145","article-title":"Terbium-161 in nuclear medicine: Preclinical and clinical progress in comparison with lutetium-177","volume":"144\u2013145","author":"Trejtnar","year":"2025","journal-title":"Nucl. Med. Biol."},{"issue":"3","key":"10.1016\/j.ejpb.2026.115123_b0150","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2967\/jnumed.124.268487","article-title":"177Lu-labeled anticlaudin 6 monoclonal antibody for targeted therapy in esophageal cancer","volume":"66","author":"Du","year":"2025","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejpb.2026.115123_b0155","unstructured":"Liang Y, Li X, Liang H, Wu T, Huang Y, Liu S, et al. Preclinical Evaluation of 5T4-Targeted [89Zr]Zr-DFO-HB5 Immuno-PET Imaging and Comparison of 161Tb vs 177Lu Radionuclide Therapy for Colorectal Cancer. J Med Chem. Published online April 15, 2026."},{"issue":"Pt B","key":"10.1016\/j.ejpb.2026.115123_b0160","article-title":"Preclinical evaluation of 89Zr\/177Lu-labeled amatuximab for theranostic application in pancreatic ductal adenocarcinoma","volume":"667","author":"Lu","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115123_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2026.107491","article-title":"89Zr\/177Lu-labeled claudin-6 antibody exhibits effective targeted radiodiagnostic and therapeutic efficacy in gynecological cancers","volume":"220","author":"Hao","year":"2026","journal-title":"Eur. J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.ejpb.2026.115123_b0170","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1021\/acs.molpharmaceut.5c01584","article-title":"Preclinical study of CDH3-targeted 89Zr\/177Lu theranostics in triple-negative breast cancer","volume":"23","author":"Tang","year":"2026","journal-title":"Mol. Pharm."},{"issue":"6","key":"10.1016\/j.ejpb.2026.115123_b0175","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1158\/1535-7163.MCT-06-0026","article-title":"Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin\/p97","volume":"5","author":"Smith","year":"2006","journal-title":"Mol. Cancer Ther."},{"issue":"8","key":"10.1016\/j.ejpb.2026.115123_b0180","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.2967\/jnumed.118.223636","article-title":"The impact of Fc\u03b3RI binding on immuno-PET","volume":"60","author":"Vivier","year":"2019","journal-title":"J. Nucl. Med."},{"issue":"3","key":"10.1016\/j.ejpb.2026.115123_b0185","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1021\/acs.molpharmaceut.3c01063","article-title":"Evaluating CD133 as a radiotheranostic target in small-cell lung cancer","volume":"21","author":"Sarrett","year":"2024","journal-title":"Mol. Pharm."},{"issue":"7","key":"10.1016\/j.ejpb.2026.115123_b0190","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1158\/1078-0432.CCR-21-1533","article-title":"Radioimmunotherapy targeting delta-like ligand 3 in small cell lung cancer exhibits antitumor efficacy with low toxicity","volume":"28","author":"Tully","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejpb.2026.115123_b0195","doi-asserted-by":"crossref","unstructured":"Yang X, Liu J, Li C, Zheng L, Lu X, Zhou Z,et al. Preclinical evaluation of 64Cu\/177Lu-labelled anti-CD30 monoclonal antibody for theranostics in CD30-positive lymphoma [published correction appears in Eur J Nucl Med Mol Imaging. 2025 May;52(6):2244.","DOI":"10.1007\/s00259-024-07059-0"},{"issue":"9","key":"10.1016\/j.ejpb.2026.115123_b0200","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1007\/s00259-019-04345-0","article-title":"Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer","volume":"46","author":"M\u00fcller","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"5","key":"10.1016\/j.ejpb.2026.115123_b0205","doi-asserted-by":"crossref","first-page":"759","DOI":"10.2967\/jnumed.115.170423","article-title":"Radioactivity deposits from 90Y, 177Lu, 111In, and 161Tb in micrometastases of various sizes: implications for radiopharmaceutical therapy","volume":"57","author":"Hindi\u00e9","year":"2016","journal-title":"J. Nucl. Med."},{"issue":"9","key":"10.1016\/j.ejpb.2026.115123_b0210","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.2967\/jnumed.122.265039","article-title":"Marshalling the potential of auger electron radiopharmaceutical therapy","volume":"64","author":"Bolcaen","year":"2023","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejpb.2026.115123_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.155290","article-title":"Ononin promotes radiosensitivity in lung cancer by inhibiting HIF-1\u03b1\/VEGF pathway","volume":"125","author":"Zhang","year":"2024","journal-title":"Phytomedicine"}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S093964112600144X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S093964112600144X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T03:21:44Z","timestamp":1781234504000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S093964112600144X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":43,"alternative-id":["S093964112600144X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115123","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical evaluation of 89Zr\/177Lu\/161Tb-labeled anti-CD228 monoclonal antibody for theranostics in skin cutaneous melanoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115123","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115123"}}